Advertisement

Topics

Search Results for "Reminder Sample Letter Prostate Cancer"

11:54 EDT 25th July 2016 | BioPortfolio

Matching Channels

Prostate Cancer in Men

Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or ...

Prostate Cancer Cellular Vaccine rDNA

Prostate specific membrane antigen PSMA

Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monit...

Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

Prostate Mab

Matching News

Reminder letter encourages more people to take bowel scope screening test

Jogging the memory with a reminder letter to those who don’t respond to their bowel scope screening invitation could mean more people would take the test, according to a Cancer Research UK-funded st...

MRI feasible for predicting prostate CA in unselected sample

(HealthDay)—Prostate multiparametric magnetic resonance imaging (MRI) is feasible for predicting prostate cancer in an unselected sample of the general population, according to a study published in ...

GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avo...

NEJM letter calls prostate cancer screening guidelines into question

Evidence now favors that prostate specific antigen (PSA) testing can help reduce the number of fatal cases of prostate cancer, contrary to earlier recommendations based on a landmark national study. R...

Prostate cancer diagnoses down from 2011 to 2013

(HealthDay)—From 2011 to 2013 there was a decrease in prostate cancer (PC) diagnoses, especially for younger men and low-risk disease, according to a research letter published online June 23 in JAMA...

New study shows the importance of family history in the risk of developing prostate cancer

Although it is already known that men with prostate cancer in the family have a higher risk of the cancer themselves, this marks the first time ever that researchers have estimated the risk of develop...

Scientists create protein signatures for accurate diagnosis of prostate cancer

Researchers at the Ontario Institute for Cancer Research and University Health Network in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that a...

Prostate Cancer: Year in Review

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the ...

Matching PubMed Articles

Gene expression profile of FVII and AR in primary prostate cancer.

The ectopic expression of coagulation Factor VII has been shown in various cancers. Recently, F7 gene has been identified as a direct target of the androgen receptor in breast cancer. In this study, w...

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can indu...

MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.

It is known that microRNAs (miRNAs) are a class of small, non-coding RNAs that act as key regulators in various physiological and pathological processes. However, the regulatory mechanisms involving m...

Immune Checkpoint Therapies in Prostate Cancer.

Advanced prostate cancer is the second leading cause of death from cancer in the United States. In the era of cancer immunotherapy, it was the first malignancy to demonstrate improved survival with a ...

Vitamin D, PTH, and calcium in relation to survival following prostate cancer.

Epidemiological studies suggest that low levels of vitamin D constitute a risk factor for prostate cancer. However, the results are conflicting, perhaps because prostate cancer is a very heterogeneous...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement